 LONDON, Nov. 04, 2021 GLOBE NEWSWIRE -- Freeline Therapeutics Holdings plc Nasdaq: FRLN the Company or Freeline, a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic debilitating diseases, today announced that data from its long-term follow-up study to its Phase 12 B-AMAZE clinical trial of FLT180a for the treatment of hemophilia B will be presented at the 63rd American Society of Hematology ASH Annual Meeting and Exposition, being held in Atlanta, Georgia and virtually on Saturday, December 11 through Tuesday, December 14, 2021. 